Novartis will spin-off Alcon
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Novartis has announced its intention to spin off its troubled Alcon eyecare division, which houses a portfolio of OTC eye-care products, into a separately-traded company listed on the Swiss stock exchange.